19 October 2015: Articles
Chromobacterium Violaceum Sepsis: Rethinking Conventional Therapy to Improve Outcome
Challenging differential diagnosis, Management of emergency care, Rare disease
Kathleen R. Richard ABCDEF , Joshua J. Lovvorn ABDEF , Sara E. Oliver BCDEF , Shannon A. Ross BCDEF , Kim W. Benner DEF , Michele Y.F. Kong ABCDEFGDOI: 10.12659/AJCR.894509
Am J Case Rep 2015; 16:740-744
Abstract
BACKGROUND: Chromobacterium violaceum (C. violaceum) is a facultative anaerobic gram-negative bacterium found in soil and water, especially in tropical and subtropical areas. Although infection in humans is rare, it is associated with significant morbidity. The bacterium is known for its resistance to multiple antimicrobials, and the possibility of relapse and reinfection. Presence of bacteremia, disseminated infection, and ineffective antimicrobial agents are predictors of mortality.
CASE REPORT: We report the case of a previously healthy 11-year-old male with C. violaceum sepsis who was exposed to stagnant water. He presented with severe septic shock and developed multi-organ system failure. Initial presumptive diagnosis was staphylococcal infection secondary to presence of skin abscesses resulting in antibiotic coverage with vancomycin, clindamycin, nafcillin and ceftriaxone. He also had multiple lung and liver abscesses. Once C. violaceum was identified, he received meropenem and ciprofloxacin, and was later discharged on ertapenem and trimethoprim-sulfamethoxazole (TMP-SMX) to complete a total of six months of antibiotics. He was diagnosed with chronic granulomatous disease (CGD) and is currently on prophylactic TMP-SMX and itraconazole. He has not had any relapses since his initial presentation.
CONCLUSIONS: This case highlights the importance of considering C. violaceum as a relevant human pathogen, and considering it early in temperate regions, particularly in cases of fulminant sepsis associated with multi-organ abscesses. Once C. violaceum is identified, appropriate antimicrobial therapy should be started promptly, and sufficient duration of treatment is necessary for successful therapy.
Keywords: Anti-Bacterial Agents - therapeutic use, Child, Chromobacterium - isolation & purification, Gram-Negative Bacterial Infections - microbiology, Sepsis - microbiology
Background
Here, we discuss a case of
Case Report
An 11-year-old male presented to a regional community hospital with gluteal abscesses. The only reported past medical history was a submental abscess at age two that was drained, and resolved without further treatment. Prior to this hospitalization, he had no other symptoms, including the absence of fever, rash, myalgia and lethargy. The parents reported that recently the patient had been in areas of stagnant water, during football practices. His lesions were initially small (Figure 1A), but progressed within two days to approximately two centimeters in diameter (Figure 1B) with deep induration of the gluteal tissue. He was placed on
Within thirty-six hours of admission, he began having shortness of breath and hypoxia. At that time, he was transferred directly to our pediatric intensive care unit (PICU) for further care. On arrival to the PICU, he complained of significant dyspnea, with grunting and retractions noted on exam. The patient was urgently intubated for impending respiratory failure and progressive shock. Physical exam revealed two large, indurated abscesses on the buttocks as well as multiple small pustules on his chest, abdomen, and extremities concerning for
After intubation, the patient briefly stabilized, but quickly developed severe acute respiratory distress syndrome (ARDS) requiring oscillatory ventilation. By eighteen hours post-transfer, his oxygenation index was consistently greater than 50 despite maximal oscillatory support, and he remained hypotensive despite aggressive fluid resuscitation and infusions of dopamine, milrinone, norepinephrine, epinephrine, and vasopressin. Due to the patient’s refractory ARDS and overwhelming septic shock, he was placed on veno-arterial extracorporeal membrane oxygenation (ECMO) in an attempt to maximize cardiac output. The patient was also oliguric on arrival and quickly progressed to anuria, requiring continuous renal replacement therapy within twelve hours of arrival.
Given the patient’s presentation with gluteal abscesses, the initial antibiotics were based on a presumptive
In total, he required fourteen days of ECMO support, and an additional five days of mechanical ventilation. He was ultimately in the PICU for a total of five weeks, and was discharged home on hospital day forty. During his hospitalization, imaging revealed multiple septic emboli and abscesses involving his lungs and liver. However, none were large enough to warrant surgical intervention. The patient was sent home on IV ertapenem (instead of meropenem due to ease of once daily dosing) and PO TMP-SMX to continue therapy for
After approximately four months of therapy, a computed tomography was obtained which showed resolution of the lung abscesses, but the scan was notable for non-enhancing liver lesions consistent with residual scarring versus abscess. Because erythrocyte sedimentation rate was still mildly elevated at that time, antibiotic therapy was continued with PO ciprofloxacin and TMP-SMX. After six months of therapy, all antibiotics were discontinued for his
Since there is a reported increased susceptibility to
Discussion
This case report highlights the importance for
As an uncommon, but highly virulent pathogen, infection with
Generally
Patients with CGD are particularly vulnerable to
Relapse can occur with
Conclusions
This case highlights the need for consideration of
References:
1.. Sneath PH, Whelan JP, Bhagwan Singh R, Edwards D: Lancet, 1953; 265; 276-77, pmid: 13085740
2.. Campbell JI, Lan NP, Qui PT: BMC Infect Dis, 2013; 13; 4, pmid: 23286235
3.. Kaufman SC, Ceraso D, Schuquernsky A: J Clin Microbiol, 1986; 23; 956-58, pmid: 3711283
4.. Sirinavin S, Techasaensiri C, Benjaponpitak S: Pediatr Infect Dis J, 2005; 24; 559-61, pmid: 15933571
5.. Macher AM, Casale TB, Fauci AS: Ann Inter Med, 1982; 97; 51-55
6.. Shao PL, Hsueh PR, Chang YC: Pediatr Infect Dis J, 2002; 21; 707-9, pmid: 12237610
7.. Vijayan AP, Anand MR, Remesh P: Indian Pediatr, 2009; 46; 721-22, pmid: 19717863
8.. Baker S, Campbel JI, Stabler R: J Clin Microbiol, 2008; 46; 3853-55, pmid: 18799697
9.. Macher AM, Casale TB, Gallin JI: Ann Intern Med, 1983; 98; 259, pmid: 6824267
10.. Sorensen RU, Jacobs MR, Shurin SB: Pediatr Infect Dis, J, 1985; 4; 701-2
11.. Martinez P, Mattar S: Rev Inst Med Trop Sao Paulo, 2007; 49; 391-93, pmid: 18157408
12.. Moore CC, Lane JE, Stephes JL: Clin Infect Dis, 2001; 32; E107-10, pmid: 11247733
13.. Yang CH, Li YH: J Chin Med Assoc, 2011; 74; 435-41, pmid: 22036134
14.. Chang CY, Lee YT, Liu KS: J Microbiol Immunol Infect, 2007; 40; 272-75, pmid: 17639170
15.. Dutta S, Dutta SK: Indian J Med Microbiol, 2003; 21; 217-18, pmid: 17643028
16.. Bosch FJ, Badenhorst L, LeRoux JA, Louw VJ: J Med Microbiol, 2008; 57; 1293-95, pmid: 18809561
17.. Midani S, Rathore M: South Med J, 1998; 91; 464-66, pmid: 9598856
18.. Teoh AYB, Hui M, Ngo KY: Hong Kong Med J, 2006; 12; 228-31, pmid: 16760554
19.. Aldridge KE, Valaninis GT, Saners CV: Diagn Microbiol Infect Dis, 1988; 10; 31-39, pmid: 3168426
20.. Fantinatti-Garboggini F, Almeida RD, Portillo VA: Genet Mol Res, 2004; 3; 134-47, pmid: 15100994
21.. Winkelstein JA, Marino MC, Johnston RB, Chronic granulomatous disease: report on a National Registry of 368 patients: Medicine, 2000; 79; 155-69, pmid: 10844935
22.. Mamlok RJ, Mamlok V, Mills GC: J. Pediat, 1987; 111; 852-54, pmid: 3681551
23.. Seigel JK, Stadler ME, Lombrano JL: Ear Nose Throat J, 2012; 91; 479-83, pmid: 23288793
24.. Brown KL, Stein A, Morrell DS: J Am Acad Dermatol, 2006; 54; S224-28, pmid: 16631946
25.. Tucker RE, Winter WG, Wilson HD: J Bone Joint Surg Am, 1979; 61; 949-51, pmid: 479248
26.. Chattopadhyay A, Kumar V, Bhat N, Rao P: J Pedatr Surg, 2002; 37; 108-10
27.. Ponte R, Jenkins SG: Pediatr Infect Dis J, 1992; 11; 583-86, pmid: 1528650
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






